The Identification of Potential Treatment Targets to Reduce the Risk of Obesity-Related Complications: A Step Toward

Luca Busetto1, Volker Schnecke2, Maria Overvad2

  • 1Department of Medicine University of Padova Padova Italy.

Obesity Science & Practice
|November 10, 2025
PubMed
Abstract

Insights

New research suggests specific body measurements after weight loss can help manage obesity-related complications. Body Mass Index (BMI) and waist-height ratio (WHtR) are proposed as key targets for reducing health risks.

Area of Science:

  • Metabolic Health
  • Obesity Medicine
  • Cardiovascular Health

Background:

  • Obesity-related complications (ORCs) pose significant health and economic challenges.
  • Current obesity management lacks established treatment targets, unlike other chronic conditions.
  • Identifying effective adiposity measures is crucial for risk reduction.

Purpose of the Study:

  • To identify an optimal adiposity measure for reducing the risk of four major obesity-related complications.
  • To evaluate absolute adiposity measures and their changes as proxies for achieving a low 10-year ORC risk.

Main Methods:

  • A population-based cohort study utilizing UK Clinical Practice Research Datalink Aurum data (18-60 years).
  • Analysis of associations between 10-year ORC risk and baseline/post-weight loss Body Mass Index (BMI) and waist-height ratio (WHtR).
  • Identification of optimal cut-offs for BMI and WHtR based on risk reduction efficacy.

Main Results:

  • Absolute post-weight change BMI and WHtR were more strongly linked to 10-year ORC risk than relative changes.
  • WHtR proved the best indicator for reduced risk of type 2 diabetes, hypertension, and atherosclerotic cardiovascular disease.
  • BMI was the most effective measure for hip/knee osteoarthritis risk. Proposed targets: BMI ≤ 27 kg/m² and WHtR ≤ 0.53.

Conclusions:

  • Obesity treatment goals should focus on absolute adiposity measures post-weight change, not just relative reductions.
  • Both BMI and WHtR are valuable metrics for setting treatment targets to mitigate ORC risk.

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
230
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
307
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
163
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
208
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
853